ANKRD30A

Across TCGA pan-cancer cohorts, ANKRD30A Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ANKRD30A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD30A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD30A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, PAAD, and LIHC are the cancer types where ANKRD30A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.819	0.612	.006	28	view →
PAAD	OS	Median	All	0.037	0.641	<.001	24	view →
LIHC	DFS	Median	All	0.193	0.549	.001	12	view →
ESCA	OS	Median	IV	0.095	0.512	.008	12	view →
READ	DFS	Median	All	0.174	0.731	.001	9	view →
PRAD	DFS	Median	All	0.139	0.778	<.001	6	view →
GBM	OS	Median	All	0.197	0.415	.049	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	0.661	0.538	.020	2	view →
SCLC	OS	Median	All	0.424	0.807	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ANKRD30A–UCEC (DFS)

Open the UCEC breakdown →